Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could bring major relief for severe eczema sufferers

NCT ID NCT06552520

Disease control Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental injection called TQH2722 in 500 adults with moderate to severe eczema (atopic dermatitis). The goal is to see if it can significantly reduce skin redness, itching, and rash compared to a placebo. Participants receive either the drug or a dummy shot, and doctors track skin improvement and any side effects over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

500 people

The number who actually took part.

Started

Oct 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The age of signing the informed consent is 18-75 years old, regardless of gender. * Meet the 2014 American Academy of Dermatology (AAD) standards, diagnosed as AD. * During screening and baseline visit, eczema area and severity score (EASI) ≥16 points; Investigator global score (IGA) ≥3 points; Affected body surface area (BSA) ≥10%; Baseline pruritus Peak Value Scale (NRS) weekly mean ≥4 points. * Have received at least 4 weeks of moderate-to-strong action or at least 2 weeks of super effective external glucocorticoid (TCS) treatment or sufficient duration of systemic glucocorticoid treatment, the efficacy is not sufficient; Or subjects cannot receive the above treatment due to adverse reactions or potential risks. Exclusion Criteria: * Used immunosuppressants/immunomodulatory drugs, ultraviolet phototherapy, systemic Chinese medicine treatment within 4 weeks before randomization. * Received topical calcineurin inhibitors (TCS), topical calcineurin inhibitors (TCI), and other topical preparations within 2 weeks before randomization. * Received anti-interleukin-4 receptor alpha (IL-4R) monoclonal antibodies, anti-ige monoclonal antibodies, or other biologic agents within 12 weeks or 5 half-lives (whichever is longer) prior to randomization. * Had received live attenuated vaccine within 12 weeks prior to randomization or planned to receive it during the study period. * Use of antihistamines within 1 week prior to randomization (unless you have received steady doses of antihistamines for at least 7 days). * Received allergen specific immunotherapy within 6 months before randomization. * There are skin comorbidities that may interfere with study evaluation. * There is a history of clinically significant illness that the investigator believes poses a risk to the safety of the subject and is poorly controlled. * A known or suspected history of immunosuppression (immune deficiency). * Subjects with any type of active malignancy or a history of malignancy (except cervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and papillary thyroid carcinoma that have been cured for more than 5 years prior to the screening period). * Subject may have active Mycobacterium tuberculosis infection. * Subjects with severe liver and kidney function impairment. * Screening period HIV antibody positive, or have a history of HIV infection. * Screening period of treponema pallidum antibody positive. * Participated in clinical trials of other drugs or medical devices within 12 weeks prior to randomization. * Treatment-requiring infections were present in the 4 weeks prior to randomization. * During the study period, subjects plan to undergo major surgical operations. * Pregnant or lactating women. * Alcohol, drug abuse and known drug dependence. * History of atopic keratoconjunctivitis with corneal involvement. * The subject has any medical or psychiatric symptoms that interfere with participation in the study or with the interpretation of the study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, 10000, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 210039, China

  • Affiliated Hospital of Qinghai University

    Xining, Qinghai, 810000, China

  • Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, 646000, China

  • Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, 221132, China

  • Anyang District Hospital, Puyang City

    Anyang, Henan, 455001, China

  • Baoji Central Hospital

    Baoji, Shanxi, 721008, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, 14040, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100050, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, 061012, China

  • Changzhou First People's Hospital

    Changzhou, Jiangsu, 213000, China

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, 610000, China

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, 610072, China

  • Chongqing Three Gorges Medical College affiliated People's Hospital

    Chongqing, Chongqing Municipality, 404100, China

  • Dermatology Hospital of Southern Medical UniversityDermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, 510000, China

  • Dezhou People's Hospital

    Dezhou, Shandong, 277102, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, 310006, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, 310009, China

  • Heilongjiang Provincial Hospital

    Harbin, Heilongjiang, 150036, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, 450000, China

  • Hunan Medical University General Hospital

    Huaihua, Hunan, 418000, China

  • Jiaxing second Hospital

    Jiaxing, Zhejiang, 545006, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, 434000, China

  • Jinhua Central Hospital

    Jinhua, Zhejiang, 321000, China

  • Liaocheng People's Hospital

    Liaocheng, Shandong, 252000, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, 545006, China

  • Nanyang city first People's Hospital

    Nanyang, Henan, 473000, China

  • Panjin Liao oil precious stone flower hospital

    Panjin, Liaoning, 124120, China

  • Peking University First Hospital Taiyuan Hospital

    Taiyuan, Shanxi, 030009, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, 518036, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang, 830002, China

  • Qiqihar Hospital of Traditional Chinese Medicine

    Qiqihar, Heilongjiang, 161005, China

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, 472000, China

  • Second Hospital of Jilin University

    Changchun, Jilin, 130041, China

  • Shandong University Qilu Hospital

    Jinan, Shandong, 250012, China

  • Shanghai Dermatology Hospital

    Shanghai, Shanghai Municipality, 545006, China

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, 030000, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, 610000, China

  • Suining Central Hospital

    Suining, Sichuan, 629000, China

  • Suzhou Municipal Hospital

    Suzhou, Jiangsu, Weiling, China

  • The Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, 067000, China

  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology

    Baotou, Inner Mongolia, 14017, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, 233004, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400010, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Zhengzhou, Henan, 471000, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650032, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, 315211, China

  • The First Affiliated Hospital of PLA Air Force Medical University

    Xi’an, Shanxi, 710032, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, 421001, China

  • The First Affiliated Hospital of Xi 'an Medical College

    Xi’an, Shanxi, 710032, China

  • The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University

    Chongqing, Chongqing Municipality, 400038, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400072, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510000, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 151100, China

  • The Second Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, 471000, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215000, China

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, 241000, China

  • The Second Affiliated Hospital of Xi 'an Jiaotong University

    Xi’an, Shanxi, 710004, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, 361021, China

  • The Second Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University

    Xi’an, Shanxi, 710032, China

  • The Second Xiangya Hospital, Central South University

    Changsha, Hunan, 410011, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, Tianjin Municipality, 300120, China

  • Tianjin First Central Hospital

    Tianjin, Tianjin Municipality, 300190, China

  • Tongling People's Hospital

    Tongling, Anhui, 244000, China

  • Wuhan University People's Hospital

    Wuhan, Hubei, 430060, China

  • Xiangya Third Hospital, Central South University

    Changsha, Hunan, 410013, China

  • Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine

    Ürümqi, Xinjiang, 830002, China

  • Yancheng First People's Hospital

    Yancheng, Jiangsu, 224005, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, 264000, China

  • Yichang Central People's Hospital

    Yichang, Hubei, 443003, China

  • Yinchuan First People's Hospital

    Yinchuan, Ningxia, 750010, China

  • Zaozhuang Municipal Hospital

    Zaozhuang, Shandong, 277102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.